Pancreatic cancer cells assemble a CXCL12-keratin 19 coating to resist immunotherapy
Authors:
- Zhikai WangZWZhikai Wang
- Ran YanRYRan Yan
- Jiayun LiJLJiayun Li
- Ya GaoYGYa Gao
- Philip MorescoPMPhilip Moresco
- Min YaoMYMin Yao
- Jaclyn F. HechtmanJHJaclyn F. Hechtman
- Matthew J. WeissMWMatthew J. Weiss
- Tobias JanowitzTJTobias Janowitz
- Douglas T. FearonDFDouglas T. Fearon
Preprint
Abstract
How pancreatic ductal adenocarcinoma (PDA) cells stimulate CXCR4 to exclude T cells and resist T cell checkpoint inhibitors is not known. Here, we find that CXCL12, the ligand for CXCR4 that is produced by the cancer-associated fibroblast, “coats” human PDA and colorectal cancer cells as covalent heterodimers with keratin 19 (KRT19). Modeling the formation of the heterodimer with three proteins shows that KRT19 binds CXCL12 and transglutaminase-2 (TGM2), and that TGM2 converts the reversible KRT19-CXCL12 complex into a covalent heterodimer. We validate this model by showing that cancer cells in mouse PDA tumors must express KRT19 and TGM2 to become coated with CXCL12, exclude T cells, and resist immunotherapy with anti-PD-1 antibody. Thus, PDA cells have a cell-autonomous means by which they capture CXCL12 to mediate immune suppression, which is potentially amenable to therapy. One Sentence Summary: Cancer cells in pancreatic ductal adenocarcinoma use transglutaminase-2 to assemble a coating comprised of covalent CXCL12-keratin 19 heterodimers that excludes T cells and mediates resistance to inhibition of the PD-1 T cell checkpoint.Keywords
This publication has 33 references indexed in Scilit:
- CD8 T Cell Exhaustion During Chronic Viral Infection and CancerAnnual Review of Immunology, 2019
- TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cellsNature, 2018
- Genomic correlates of response to CTLA-4 blockade in metastatic melanomaScience, 2015
- T cell exclusion, immune privilege, and the tumor microenvironmentScience, 2015
- Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancerScience, 2015
- Genetic Basis for Clinical Response to CTLA-4 Blockade in MelanomaNew England Journal of Medicine, 2014
- Chemokines and Chemokine Receptors: Positioning Cells for Host Defense and ImmunityAnnual Review of Immunology, 2014
- Regulatory T Cells: Mechanisms of Differentiation and FunctionAnnual Review of Immunology, 2012
- Abstract 5435: Tolcapone inhibits catechol-O-methyl transferase-mediated methylation of (-)-epigallocatechin-3-gallate in vivoCancer Research, 2012
- Type, Density, and Location of Immune Cells Within Human Colorectal Tumors Predict Clinical OutcomeScience, 2006